MJP Associates’s iBio IBIO Stock Holding History

MJP Associates’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-40	Closed	-$3K	–	143
2022 Q3	$3K	Buy	+40	New	+$5.51K	﹤0.01%	128

Other funds holding IBIO

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

MJP Associates's IBIO Position: Q4 2022 in Review

MJP Associates sold out of iBio (IBIO) in Q4 2022, closing a stake of 40 shares — an estimated $3K sold.

MJP Associates first reported a position in IBIO in Q3 2022 and held it in 1 quarter. The position peaked at $3K in Q3 2022. 36 funds tracked by Wall St. Rank hold IBIO as of Q4 2022.

MJP Associates reported no remaining iBio position as of Q4 2022 after selling out during the quarter.
MJP Associates sold 40 iBio shares in Q4 2022, an estimated $3K.
MJP Associates first reported a position in iBio in Q3 2022 and held it in 1 quarter.
MJP Associates's iBio position peaked at $3K in Q3 2022.
36 funds tracked by Wall St. Rank held iBio as of Q4 2022.

Based on MJP Associates's 13F filing for Q4 2022, filed 20 Jan 2023.